References
- Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006; 368: 843–54
- Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47–56
- Eisbruch A, Dawson LA, Kim HM, Bradford CR, Terrell JE, Chepeha DB, et al. Conformal and intensity modulated irradiation of head and neck cancer: The potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg 1999; 53: 271–5
- Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66: 981–91
- Eisbruch A, Ship JA, Dawson LA, Kim HM, Bradford CR, Terrell JE, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003; 27: 832–7
- Gregoire V, Daisne JF, Geets X, Levendag P. Selection and delineation of target volumes in head and neck tumors: Beyond ICRU definition. Rays 2003; 28: 217–24
- Breen S Publicover J De Silva S Pond G Brock K O'Sullivan B et al. Intra- and inter-observer variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys ( in press).
- RTOG. Phase I/II study of conformal and intensity modulated irradiation for oropharyngeal cancer. Protocol No. 0022. Philadelphia: Radiation Therapy Oncology Group; 2001.
- Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. Cmaj 2005; 172: 1461–71
- Ramm U, Damrau M, Mose S, Manegold KH, Rahl CG, Bottcher HD. Influence of CT contrast agents on dose calculations in a 3D treatment planning system. Phys Med Biol 2001; 46: 2631–5
- Kassas B, Mourtada F, Horton JL, Lane RG. Contrast effects on dosimetry of a partial breast irradiation system. Med Phys 2004; 31: 1976–9
- Weber DC, Rouzaud M, Miralbell R. Bladder opacification does not significantly influence dose distribution in conformal radiotherapy of prostate cancer. Radiother Oncol 2001; 59: 95–7
- Wertz H, Jakel O. Influence of iodine contrast agent on the range of ion beams for radiotherapy. Med Phys 2004; 31: 767–73
- Clement O, Robert P, Cuenod CA, Siauve N, Sobotka A, Kahn E, et al. Functional imaging of tumors using CT and iodinated contrast media of different molecular weights. Acad Radiol 2002; 9(Suppl 1)S212–S214
- Liauw SL, Amdur RJ, Mendenhall WM, Palta J, Kim S. The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. Am J Clin Oncol 2005; 28: 456–9
- Choi Y, Kim JK, Lee HS, Hur WJ, Hong YS, Park S, et al. Influence of intravenous contrast agent on dose calculations of intensity modulated radiation therapy plans for head and neck cancer. Radiother Oncol 2006; 81: 158–62